GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cartesian Therapeutics Inc (STU:1S70) » Definitions » Institutional Ownership

Cartesian Therapeutics (STU:1S70) Institutional Ownership : 7.06% (As of Jun. 06, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cartesian Therapeutics Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cartesian Therapeutics's institutional ownership is 7.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cartesian Therapeutics's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cartesian Therapeutics's Float Percentage Of Total Shares Outstanding is 11.34%.


Cartesian Therapeutics Institutional Ownership Historical Data

The historical data trend for Cartesian Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cartesian Therapeutics Institutional Ownership Chart

Cartesian Therapeutics Historical Data

The historical data trend for Cartesian Therapeutics can be seen below:

2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31 2024-04-30
Institutional Ownership 21.88 21.39 21.05 18.52 19.57 20.37 21.23 22.32 22.83 7.06

Cartesian Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Cartesian Therapeutics (STU:1S70) Business Description

Traded in Other Exchanges
Address
65 Grove Street, Watertown, MA, USA, 02472
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. Its product pipeline includes MMA-101, SEL-212 for Chronic Severe Gout, SEL-313 for Ornithine Transcarbamylase Deficiency (OTC), and others.

Cartesian Therapeutics (STU:1S70) Headlines

No Headlines